|
|
Дата |
|---|
| 18.11.2026 |
| 17.11.2026 |
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
25.08
|
33.84
|
30.60
|
30.445
|
32.85
|
31.35
|
|
|
12 008 026.66
|
3 560.00
|
|
27.00
|
33.84
|
28.62
|
28.62
|
31.78
|
30.92
|
|
|
15 090 665.25
|
4 673.00
|
|
11.54
|
33.84
|
31.04
|
28.175
|
32.395
|
28.61
|
|
|
7 550 652.32
|
6 708.00
|
|
12.72
|
33.84
|
32.83
|
31.20
|
33.00
|
31.20
|
|
|
6 027 513.41
|
4 134.00
|
|
13.14
|
33.84
|
32.00
|
30.90
|
33.435
|
32.83
|
|
|
16 109 729.36
|
6 685.00
|
|
12.89
|
33.84
|
31.50
|
31.01
|
33.56
|
31.44
|
|
|
10 671 061.05
|
4 444.00
|
|
12.52
|
50.04
|
30.36
|
29.84
|
31.57
|
31.30
|
|
|
7 353 595.44
|
3 194.00
|
|
12.12
|
48.46
|
30.18
|
28.77
|
30.68
|
30.36
|
|
|
5 593 397.49
|
3 017.00
|
|
18.25
|
47.96
|
28.91
|
28.91
|
31.175
|
30.50
|
|
|
11 184 286.82
|
3 942.00
|
|
27.00
|
46.12
|
29.16
|
27.9414
|
29.335
|
28.80
|
|
|
5 464 628.35
|
3 212.00
|
Lycia Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. Its immunoglobulin E (IgE) portfolio consists of LCA-0061 and LCA-0062. The LCA-0061 is an antibody-small molecule conjugate cataLYTAC degrader designed to target and degrade IgE, a known driver of multiple allergic diseases, including food allergy, allergic asthma, allergic rhinitis, chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps.
The LCA-0062 bispecific antibody cataLYTAC degrader is designed to target and degrade IgE, it is designed to degrade multiple copies of IgE per LYTAC degrader. LCA-0321 is a protein-small molecule conjugate classic LYTAC degrader which is designed to selectively degrade TRAbs, the pathogenic drivers of Graves' disease.
Показать все Скрыть